Pim Cuijpers1, Eirini Karyotaki1, Dikla Eckshtain2, Mei Yi Ng3, Katherine A Corteselli4, Hisashi Noma5, Soledad Quero6, John R Weisz4. 1. Department of Clinical, Neuro, and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 2. Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Boston. 3. Department of Psychology and Center for Children and Families, Florida International University, Miami. 4. Department of Psychology, Harvard University, Cambridge, Massachusetts. 5. Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan. 6. Department of Basic, Clinical Psychology and Psychobiology, Universitat Jaume I, Castellón, Spain.
Abstract
Importance: It is not clear whether psychotherapies for depression have comparable effects across the life span. Finding out is important from a clinical and scientific perspective. Objective: To compare the effects of psychotherapies for depression between different age groups. Data Sources: Four major bibliographic databases (PubMed, PsychINFO, Embase, and Cochrane) were searched for trials comparing psychotherapy with control conditions up to January 2019. Study Selection: Randomized trials comparing psychotherapies for depression with control conditions in all age groups were included. Data Extraction and Synthesis: Effect sizes (Hedges g) were calculated for all comparisons and pooled with random-effects models. Differences in effects between age groups were examined with mixed-effects subgroup analyses and in meta-regression analyses. Main Outcomes and Measures: Depressive symptoms were the primary outcome. Results: After removing duplicates, 16 756 records were screened and 2608 full-text articles were screened. Of these, 366 trials (36 702 patients) with 453 comparisons between a therapy and a control condition were included in the qualitative analysis, including 13 (3.6%) in children (13 years and younger), 24 (6.6%) in adolescents (≥13 to 18 years), 19 (5.2%) in young adults (≥18 to 24 years), 242 (66.1%) in middle-aged adults (≥24 to 55 years), 58 (15.8%) in older adults (≥55 to 75 years), and 10 (2.7%) in older old adults (75 years and older). The overall effect size of all comparisons across all age groups was g = 0.75 (95% CI, 0.67-0.82), with very high heterogeneity (I2 = 80%; 95% CI: 78-82). Mean effect sizes for depressive symptoms in children (g = 0.35; 95% CI, 0.15-0.55) and adolescents (g = 0.55; 95% CI, 0.34-0.75) were significantly lower than those in middle-aged adults (g = 0.77; 95% CI, 0.67-0.87). The effect sizes in young adults (g = 0.98; 95% CI, 0.79-1.16) were significantly larger than those in middle-aged adults. No significant difference was found between older adults (g = 0.66; 95% CI, 0.51-0.82) and those in older old adults (g = 0.97; 95% CI, 0.42-1.52). The outcomes should be considered with caution because of the suboptimal quality of most of the studies and the high levels of heterogeneity. However, most primary findings proved robust across sensitivity analyses, addressing risk of bias, target populations included, type of therapy, diagnosis of mood disorder, and method of data analysis. Conclusions and Relevance: Trials included in this meta-analysis reported effect sizes of psychotherapies that were smaller in children than in adults, probably also smaller in adolescents, that the effects may be somewhat larger in young adults, and without meaningful differences between middle-aged adults, older adults, and older old adults.
Importance: It is not clear whether psychotherapies for depression have comparable effects across the life span. Finding out is important from a clinical and scientific perspective. Objective: To compare the effects of psychotherapies for depression between different age groups. Data Sources: Four major bibliographic databases (PubMed, PsychINFO, Embase, and Cochrane) were searched for trials comparing psychotherapy with control conditions up to January 2019. Study Selection: Randomized trials comparing psychotherapies for depression with control conditions in all age groups were included. Data Extraction and Synthesis: Effect sizes (Hedges g) were calculated for all comparisons and pooled with random-effects models. Differences in effects between age groups were examined with mixed-effects subgroup analyses and in meta-regression analyses. Main Outcomes and Measures: Depressive symptoms were the primary outcome. Results: After removing duplicates, 16 756 records were screened and 2608 full-text articles were screened. Of these, 366 trials (36 702 patients) with 453 comparisons between a therapy and a control condition were included in the qualitative analysis, including 13 (3.6%) in children (13 years and younger), 24 (6.6%) in adolescents (≥13 to 18 years), 19 (5.2%) in young adults (≥18 to 24 years), 242 (66.1%) in middle-aged adults (≥24 to 55 years), 58 (15.8%) in older adults (≥55 to 75 years), and 10 (2.7%) in older old adults (75 years and older). The overall effect size of all comparisons across all age groups was g = 0.75 (95% CI, 0.67-0.82), with very high heterogeneity (I2 = 80%; 95% CI: 78-82). Mean effect sizes for depressive symptoms in children (g = 0.35; 95% CI, 0.15-0.55) and adolescents (g = 0.55; 95% CI, 0.34-0.75) were significantly lower than those in middle-aged adults (g = 0.77; 95% CI, 0.67-0.87). The effect sizes in young adults (g = 0.98; 95% CI, 0.79-1.16) were significantly larger than those in middle-aged adults. No significant difference was found between older adults (g = 0.66; 95% CI, 0.51-0.82) and those in older old adults (g = 0.97; 95% CI, 0.42-1.52). The outcomes should be considered with caution because of the suboptimal quality of most of the studies and the high levels of heterogeneity. However, most primary findings proved robust across sensitivity analyses, addressing risk of bias, target populations included, type of therapy, diagnosis of mood disorder, and method of data analysis. Conclusions and Relevance: Trials included in this meta-analysis reported effect sizes of psychotherapies that were smaller in children than in adults, probably also smaller in adolescents, that the effects may be somewhat larger in young adults, and without meaningful differences between middle-aged adults, older adults, and older old adults.
Authors: John R Weisz; Sofie Kuppens; Mei Yi Ng; Dikla Eckshtain; Ana M Ugueto; Rachel Vaughn-Coaxum; Amanda Jensen-Doss; Kristin M Hawley; Lauren S Krumholz Marchette; Brian C Chu; V Robin Weersing; Samantha R Fordwood Journal: Am Psychol Date: 2017 Feb-Mar
Authors: Dikla Eckshtain; Sofie Kuppens; Ana Ugueto; Mei Yi Ng; Rachel Vaughn-Coaxum; Katherine Corteselli; John R Weisz Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-04-17 Impact factor: 8.829
Authors: A Jobst; E-L Brakemeier; A Buchheim; F Caspar; P Cuijpers; K P Ebmeier; P Falkai; R Jan van der Gaag; W Gaebel; S Herpertz; T Kurimay; L Sabaß; K Schnell; E Schramm; C Torrent; D Wasserman; J Wiersma; F Padberg Journal: Eur Psychiatry Date: 2016-02-06 Impact factor: 5.361
Authors: Ulf Jonsson; Göran Bertilsson; Per Allard; Harald Gyllensvärd; Anne Söderlund; Anne Tham; Gerhard Andersson Journal: PLoS One Date: 2016-08-18 Impact factor: 3.240
Authors: Yara J Toenders; Liliana Laskaris; Christopher G Davey; Michael Berk; Yuri Milaneschi; Femke Lamers; Brenda W J H Penninx; Lianne Schmaal Journal: Mol Psychiatry Date: 2021-10-11 Impact factor: 15.992
Authors: Ivan Aprahamian; Marcus K Borges; Denise J C Hanssen; Hans W Jeuring; Richard C Oude Voshaar Journal: Clin Interv Aging Date: 2022-06-22 Impact factor: 3.829
Authors: Kim Fredman Stein; Jennifer L Allen; Ross Robinson; Cassandra Smith; Katherine Sawyer; Gemma Taylor Journal: BMC Psychiatry Date: 2022-06-21 Impact factor: 4.144
Authors: Sanne P A Rasing; Yvonne A J Stikkelbroek; Wouter den Hollander; Heleen Riper; Maja Deković; Maaike H Nauta; Daan H M Creemers; Marianne C P Immink; Mariken Spuij; Denise H M Bodden Journal: Int J Environ Res Public Health Date: 2021-03-17 Impact factor: 3.390
Authors: Claire Rosalie van Genugten; Josien Schuurmans; Adriaan W Hoogendoorn; Ricardo Araya; Gerhard Andersson; Rosa Baños; Cristina Botella; Arlinda Cerga Pashoja; Roman Cieslak; David Daniel Ebert; Azucena García-Palacios; Jean-Baptiste Hazo; Rocío Herrero; Jérôme Holtzmann; Lise Kemmeren; Annet Kleiboer; Tobias Krieger; Ewelina Smoktunowicz; Ingrid Titzler; Naira Topooco; Antoine Urech; Johannes H Smit; Heleen Riper Journal: JMIR Ment Health Date: 2021-12-06